Literature DB >> 28576166

Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.

Kelly E Henry1, Gary A Ulaner2, Jason S Lewis3.   

Abstract

Increased human epidermal growth factor receptor 2 (HER2) expression is a hallmark of aggressive breast cancer. Imaging modalities have the potential to diagnose HER2-positive breast cancer and detect distant metastases. The heterogeneity of HER2 expression between primary and metastatic disease sites limits the value of tumor biopsies. Molecular imaging is a noninvasive tool to assess HER2-positive primary lesions and metastases. Radiolabeled antibodies, antibody fragments, and affibody molecules devise a reliable and quantitative method for detecting HER2-positive cancer using PET. HER2-targeted PET imaging is a valuable clinical tool with respect to both the care and maintenance of patients with breast cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; CT; HER2; Imaging; Metastasis; PET; Radiotracers; SPECT

Mesh：

Substances：

Year:  2017        PMID： 28576166      PMCID： PMC5545121          DOI： 10.1016/j.cpet.2017.02.001

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  51 in total

1.  64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.

Authors:  Kenji Tamura; Hiroaki Kurihara; Kan Yonemori; Hitoshi Tsuda; Junko Suzuki; Yuzuru Kono; Natsuki Honda; Makoto Kodaira; Harukaze Yamamoto; Mayu Yunokawa; Chikako Shimizu; Koki Hasegawa; Yousuke Kanayama; Satoshi Nozaki; Takayuki Kinoshita; Yasuhiro Wada; Shusaku Tazawa; Kazuhiro Takahashi; Yasuyoshi Watanabe; Yasuhiro Fujiwara
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

2.  Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer.

Authors:  Sietske B M Gaykema; Adrienne H Brouwers; Sjoerd Hovenga; Marjolijn N Lub-de Hooge; Elizabeth G E de Vries; Caroline P Schröder
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

3.  Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.

Authors:  E C Dijkers; T H Oude Munnink; J G Kosterink; A H Brouwers; P L Jager; J R de Jong; G A van Dongen; C P Schröder; M N Lub-de Hooge; E G de Vries
Journal:  Clin Pharmacol Ther       Date:  2010-03-31       Impact factor: 6.875

4.  Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Authors:  Joanne E Mortimer; James R Bading; David M Colcher; Peter S Conti; Paul H Frankel; Mary I Carroll; Shan Tong; Erasmus Poku; Joshua K Miles; John E Shively; Andrew A Raubitschek
Journal:  J Nucl Med       Date:  2013-12-12       Impact factor: 10.057

5.  Phase I and II clinical trials of trastuzumab.

Authors:  J Baselga
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

7.  Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Patrick J Perik; Marjolijn N Lub-De Hooge; Jourik A Gietema; Winette T A van der Graaf; M Alexander de Korte; Sharon Jonkman; Jos G W Kosterink; Dirk J van Veldhuisen; Dirk T Sleijfer; Pieter L Jager; Elisabeth G E de Vries
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

8.  (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Authors:  Hiroaki Kurihara; Akinobu Hamada; Masayuki Yoshida; Schuichi Shimma; Jun Hashimoto; Kan Yonemori; Hitomi Tani; Yasuji Miyakita; Yousuke Kanayama; Yasuhiro Wada; Makoto Kodaira; Mayu Yunokawa; Harukaze Yamamoto; Chikako Shimizu; Kazuhiro Takahashi; Yasuyoshi Watanabe; Yasuhiro Fujiwara; Kenji Tamura
Journal:  EJNMMI Res       Date:  2015-03-12       Impact factor: 3.138

9.  Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Authors:  Jens Sörensen; Irina Velikyan; Dan Sandberg; Anders Wennborg; Joachim Feldwisch; Vladimir Tolmachev; Anna Orlova; Mattias Sandström; Mark Lubberink; Helena Olofsson; Jörgen Carlsson; Henrik Lindman
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

Review 10.  Nanobody: the "magic bullet" for molecular imaging?

Authors:  Rubel Chakravarty; Shreya Goel; Weibo Cai
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556
View more
  19 in total

1.  Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.

Authors:  Longguang Tang; Chenyu Peng; Bowen Tang; Zijing Li; Xiangyu Wang; Jindian Li; Fei Gao; Lumei Huang; Duo Xu; Pu Zhang; Rongqiang Zhuang; Xinhui Su; Xiaoyuan Chen; Xianzhong Zhang
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

2.  Correcting for targeted and control agent signal differences in paired-agent molecular imaging of cancer cell-surface receptors.

Authors:  Negar Sadeghipour; Scott C Davis; Kenneth M Tichauer
Journal:  J Biomed Opt       Date:  2018-06       Impact factor: 3.170

3.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

Review 4.  PET Imaging of Receptor Tyrosine Kinases in Cancer.

Authors:  Weijun Wei; Dalong Ni; Emily B Ehlerding; Quan-Yong Luo; Weibo Cai
Journal:  Mol Cancer Ther       Date:  2018-08       Impact factor: 6.261

5.  First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Authors:  Gary A Ulaner; Serge K Lyashchenko; Christopher Riedl; Shutian Ruan; Pat B Zanzonico; Diana Lake; Komal Jhaveri; Brian Zeglis; Jason S Lewis; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2017-11-16       Impact factor: 10.057

6.  Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.

Authors:  Kelly E Henry; Thomas R Dilling; Dalya Abdel-Atti; Kimberly J Edwards; Michael J Evans; Jason S Lewis
Journal:  J Nucl Med       Date:  2017-08-28       Impact factor: 10.057

Review 7.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 8.  Receptor Occupancy Imaging Studies in Oncology Drug Development.

Authors:  Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott
Journal:  AAPS J       Date:  2018-03-08       Impact factor: 4.009

9.  Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.

Authors:  Gary A Ulaner; Jorge A Carrasquillo; Christopher C Riedl; Randy Yeh; Vaios Hatzoglou; Dara S Ross; Komal Jhaveri; Sarat Chandarlapaty; David M Hyman; Brian M Zeglis; Serge K Lyashchenko; Jason S Lewis
Journal:  Radiology       Date:  2020-06-09       Impact factor: 11.105

Review 10.  Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.